E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Hormonal diseases [C19] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10000599 |
E.1.2 | Term | Acromegaly |
E.1.2 | System Organ Class | 10014698 - Endocrine disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The Primary Objective is to evaluate the effects
of PDE5Ai on LV remodeling (kinetic and geometry parameters) at cine cardiac magnetic resonance (CMR) with tagging technique
and contrast-enhanced and at 2D echocardiography with Tissue Doppler Imaging and speckle tracking in patients with Acromegaly
cardiomyopathy |
Valutazione degli effetti dei PDE5i sul rimodellamento cardiaco (geometria e cinetica) alla cine
Risonanza Magnetica cardiaca con tecnica tagging e mezzo di contrasto e all’ Ecocardiografia 2-D con Tissue Doppler Imaging e
tecnica speckle tracking in uomini e donne affetti da Acromegalia |
|
E.2.2 | Secondary objectives of the trial |
-to measure the effect of PDE5Ai on LV
fibrosis at T1-mapping CMR at baseline and after PDE5Ai administration.
-to measure the effect of PDE5Ai on cardiac performance at cine CMR and at 2D echocardiography with Tissue Doppler Imaging
and speckle tracking at baseline and after PDE5Ai administration.
-to measure the effect PDE5Ai of circulating cardiac-inflammatory-metabolic-endothelial molecular markers
-to measure the effect on body composition |
- caratterizzazione della fibrosi cardiaca tramite T1 mapping prima e dopo trattamento con PDE5Ai
- Misurare l’inotropismo e la contrattilità cardiaca tramite cardio RMN e ecocardiografia 2-D, Tissue Doppler Imaging e speckle
tracking, prima e dopo trattamento
- Misurare l'effetto sui marcatori molecolari infiammatori, metabolici ed endoteliali
- misurare l'effetto sulla composizione corporea |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
age>18 yrs; patients (men and women) with previous diagnosis of Acromegaly, surgically and/or clinically treated according to current
guidelines, with stable parameters of Acromegaly disease in the last 3 months, and with concomitant cardiac hypertrophy and/or diastolic
dysfunction developed independently of Acromegaly care and detected by 2D echocardiography |
età> 18 anni; pazienti con precedente diagnosi di Acromegalia chirurgicamente e/o clinicamente trattata in accordo
con le linee guida correnti, con parametri dell'Acromegalia stabili negli ultimi 3 mesi, e concomitante ipertrofia ventricolare sinistra e/o
disfunzione diastolica sviluppata indipendentemente dal trattamento dell'Acromegalia e valutata all’ecocardiografia 2-d |
|
E.4 | Principal exclusion criteria |
congenital or valvular cardiomyopathy, recent ischemic heart disease or revascularization after a myocardical infarction (MI), and
contraindications to tadalafil 20 mg use (hypersensitivity to tadalafil, nitrates use, severe cardiovascular disorders (in the past 6 months) such as unstable angina or severe heart failure (NYHA II or III), or a stroke or myocardial infarction, heart rhythm problems, blood pressure <90/50 mmHg, severe hepatic or kidney impairment, and known hereditary degenerative retinal disorders such as retinitis pigmentosa, history of NAION)
and to MRI examination
- pregnant or lactating women |
Cardiomiopatie congenite o valvolari, recente infarto del miocardio o rivascolarizzazione dopo infarto del miocardio,
controindicazioni all’uso del tadalafil 20 mg (ipersensibilità al tadalafil; uso di nitroderivati; patologie cardiovascolari gravi negli ultimi sei mesi come angina instabile o scompenso cardiaco grave, classe NYHA II o III, ictus, infarto del miocardio, aritmie cardiache, pressione arteriosa <90/50 mmHg, insufficienze epatiche o renali gravi, note patologie ereditarie degenerative della retina come la retinite pigmentosa, storia di NAION);
e a sottoporsi alla Risonanza Magnetica.
- donne in gravidanza o allattamento |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change of Left ventricular torsion (°)
assessed through CMR with tagging and 2D echocardiography before and after treatment |
Cambiamento della torsione (°) del ventricolo sinistro valutata tramite RMC con tagging e ecocardiografia 2D prima e dopo il trattamento |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After 5 months of treatment |
Dopo 5 mesi di trattamento |
|
E.5.2 | Secondary end point(s) |
1. Quantification of Myocardial fibrosis assessed with T1-mapping to estabilish new parameters for the carachterization of cardiomyophaty in Acromegaly and effects of the treatment, assessed through CMR before and after treatment
2. Assessment of cardiac remodeling and inflammatory indices, endothelial function markers, oxidative stress markers in monocytes, and correlation with cardiac parameters assessed through CMR
3. Assessment of circulating microRNAs from plasma and white blood cells and correlation of their levels to basal torsion, strain and fibrosis
4. Assessment of circulating microRNAs from plasma and white blood cells and correlation of their levels torsion, strain and fibrosis after treatment
5. Assessment of circulating pro-fibrotic and pro-inflammatory chemokines (MCP-1 and TGF-beta) and correlation to torsion, strain and fibrosis at time 0 and after treatment
6. Change of parameters of body composition evaluated by MOC with total body DEXA scan
7. Change of cardiac strain (σ - longitudinal
shortening: strain %), and of parameters of cardiac geometry and performance assessed through CMR with tagging and 2D
echocardiography before and after treatment |
1. Quantificazione della fibrosi miocardica con T1-mapping per stabilire nuovi parametri per la caratterizzazione della cardiomiopatica nella Acromegalia e gli effetti del trattamento, valutati tramite RMC prima e dopo il trattamento
2. Valutazione dei marcatori di rimodellamento cardiaco, infiammazione, funzione endoteliale e stress ossidativo nei monociti e correlazione con i parametri cardiaci misurati tramite RMC
3. Valutazione dei microRNA circolanti da plasma e globuli bianchi e correlazione dei loro livelli con torsione, strain e fibrosi al basale
4. Valutazione dei microRNA circolanti da plasma e globuli bianchi e correlazione dei loro livelli con torsione, strain e fibrosi dopo trattamento
5. Valutazione delle chemochine circolanti pro-fibrotiche e pro-infiammatorie (MCP-1 e TGF-beta) e correlazione con torsione, strain e fibrosi al T0 e dopo trattamento
6. VAriazione dei parametri di composizione corporea valutati tramite MOC con tecnica DEXA total body
7. Cambiamento dello strain cardiaco (σ - accorciamento longitudinale in %), e dei parametri di geometria e performance cardiaca valutati tramite RMC con tagging e ecocardiografia 2D prima e dopo il trattamento
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. 5 months after treatment
2. 5 months after treatment
3. T0 before treatment
4. 5 months after treatment
5. Before (T0) and after treatment (5 months)
6. 5 months after treatment
7. 5 months after treatment |
1. 5 mesi dopo il trattamento
2. 5 mesi dopo il trattamento
3. T0 pre-trattamento
4. 5 mesi dopo il trattamento
5. Prima (T0) e dopo il trattamento (5 mesi)
6. 5 mesi dopo il trattamento
7. 5 mesi dopo il trattamento |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 1 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |